What type of study is this?

September 5, 2025Open Access

Meta-analysis of the efficacy of rituximab in the management of cryoglobulinemic vasculitis

Key Points

Rituximab therapy led to a notable complete clinical response rate of 67% in patients with cryoglobulinemic vasculitis.
Significant improvements in serum C4 levels were observed at both 6- and 12-month follow-ups, indicating treatment efficacy.
Cryoglobulin levels were significantly decreased after treatment, supporting rituximab's role in managing symptoms.
Further validation through high-quality randomized controlled trials is needed to confirm these promising findings.

Abstract

Introduction A primary goal of this study was to systematically assess the efficacy of rituximab (RTX) in treating cryoglobulinemic vasculitis (CV). Methods A prospectively registered meta-analysis was conducted to examine eligible randomized controlled trials (RCTs) or cohort studies through searches across PubMed, Embase, Cochrane Library, and Web of Science, with a search period up to February 12, 2025. Data analysis was conducted utilizing STATA 16.0. Results Incorporating data from 12 studies involving 287 patients, CV patients who received RTX therapy demonstrated notable complete clinical response outcomes (Rate = 0.67, 95% confidence interval (95%CI): 0.61, 0.73) and a good clinical response rate. In addition, patients showed significant relief in symptoms such as skin purpura and skin ulcer (Rate = 0.92, 95%CI: 0.86,0.98). The meta-analysis findings indicated a notable enhancement in serum C4 levels in CV patients following treatment (mean difference (MD) = 0.06, 95%CI: 0.04, 0.07), both at 6-month (MD = 0.07, 95%CI: 0.05, 0.09) and 12-month (MD = 0.07, 95%CI: 0.03, 0.11) follow-ups. These findings suggest a gradual improvement in the underlying condition. The levels of IgM were significantly reduced following treatment (MD = −0.48, 95%CI: −0.65, −0.31), both at 6-month (MD = −1.05, 95%CI: −1.57, −0.52) and 12-month (MD = −0.59, 95%CI:−0.80, −0.38) follow-ups. The levels of cryoglobulin were also decreased following treatment (MD = −0.53, 95%CI: −0.80, −0.26), both at 6-month (MD = −0.67, 95%CI: −0.99, −0.35) and 12-month (MD = −0.67, 95%CI: −1.15, −0.19) follow-ups. Similarly, rheumatoid factor (RF) levels significantly decreased after treatment (MD = −318.20,95%CI:−364.66,−271.73) and remained low at the 6-month follow-up (MD = −287.78, 95%CI:−511.58,−63.97). Discussion The meta-analysis supports the favorable clinical efficacy of rituximab in the management of CV patients. However, further validation through additional high-quality RCTs is warranted to solidify its effectiveness. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024565790 .

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Ling et al. (Fri,) studied this question.

synapsesocial.com/papers/68bb42212b87ece8dc9589dc https://doi.org/https://doi.org/10.3389/fmed.2025.1591366

Bookmark

View Full Paper